Proveca focuses on the re-engineering of existing generic medicines to make them appropriate for use by young people. The company is developing and commercialisng medicines for children in the fields of cardiology, neurology and pain management.
Proveca gains fourth key agreement with EMA
ALBION INVESTS £2.6M IN PHARMA FIRM PROVECA
Proveca raises £4m to launch children’s drug Sialanar in Europe,
Helen Shaw of Proveca named in BioBusiness Top 50 Movers & Shakers